Edition:
United States

John Miller

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Dec 11 2017

Roche: Tecentriq cocktail slows kidney cancer progression

ZURICH Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday.

Dec 08 2017

Roche study finds cancer 'Velcro' that halts T-cell attack

ZURICH Scientists at Swiss drugmaker Roche said on Friday they may have discovered why some tumors resist new immunotherapy drugs as well as a possible means of turning the tables to incite a T-cell attack.

Dec 07 2017

Roche drug cocktail doubles chance of holding lung cancer at bay

ZURICH Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented.

Dec 07 2017

Roche drug cocktail doubles chance of holding lung cancer at bay

ZURICH, Dec 7 Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented.

Dec 04 2017

With new plan, Swiss pin anti-extremism hopes on prevention

ZURICH Switzerland released a national plan on Monday to prevent violent extremism, including training teachers and coaches to recognize warning signs and re-integrating people who have already been radicalized.

Nov 27 2017

Julius Baer CEO Collardi quits suddenly to take Pictet job‍​

ZURICH Julius Baer said CEO Boris Collardi unexpectedly resigned at the weekend to take a new role at rival Pictet Group, and appointed its top risk officer to replace him "for the foreseeable future".

Nov 24 2017

Clariant snubs review demand as showdown with White Tale looms

ZURICH Clariant on Friday rejected its largest shareholder White Tale's demand for an independent strategic review and three board seats, setting up a showdown with the activist investor which blocked its $20 billion merger with Huntsman .

Nov 20 2017

Roche stock up $12 billion on cancer, hemophilia trials; rivals hit

ZURICH Roche shares were lifted on Monday by two trial wins for its new cancer and hemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines.

Nov 13 2017

Sonova misses sales, profit forecasts as U.S. overhaul bites

ZURICH Swiss hearing aid maker Sonova reported first-half results that fell short of analyst expectations, as sales in the United States were dented by an overhaul of the company's retail network there.

Nov 10 2017

Novartis posts eye drug data amid play for Eylea's turf

ZURICH Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary